Feb 15, 2021 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q3 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) There will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.
Jason D'souza - Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy
Thank you, moderator. Welcome to Glenmark's Q3 earnings call.
Before we start the call, the review of operations for the quarter ended December 31, 2020. For the third quarter of FY '21, Glenmark's consolidated revenue was at INR 27,867 million, recording an increase of 1.87%. For the third quarter, Glenmark consolidated sales was at INR 27,605 million, recording an increase of 3.88%. For the 9 months ended December 31, Glenmark's consolidated revenue was INR 80,840 million, recording an increase of 2.67%.
Glenmark issued $200 million,
Q3 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Feb 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers